Guest:
Dr. Anil Bhushan is a Professor at the University of California, San Francisco School of Medicine and Co-Founder of Deciduous Therapeutics, an aging therapeutics company developing a novel class of immune-modulatory therapies. His lab focuses on understanding how the immune system senses and tunes its response to senescent cells in disease and aging, and was one of the first to show the role of clearing senescent cells in models of type 1 diabetes.
Featured Products and Resources:
The Immunology Science Round Up
Natural Resistance to SARS-CoV-2 – While some individuals express a prenylated version of the OAS1 gene that inhibits SARS-CoV-2, researchers found that others express a version that does not detect SARS-CoV-2.
A New Target for Cancer Immunotherapy – Using in vivo CRISPR screens, scientists identified new immune targets regulating the tumor microenvironment, and revealed that knocking out the E3 ubiquitin ligase Cop1 in cancer cells enhances anti-tumor immunity.
Cognate Recognition of Microbial Antigens – Researchers speculate that dominant proinflammatory T cell clones might provide a therapeutic target in human inflammatory bowel disease.
Immune Escape in Colorectal Cancer – Using new models of colorectal cancer with defined neoantigens, scientists described a mechanism of early T cell dysfunction in immunotherapy refractory tumors and strategies to overcome it.
Image courtesy of Dr. Anil Bhushan